To investigate the clinical impact of MUC6 on HNSCC progression, we used UALCAN and GEPIA 2 to assess the relationship between the cellular levels of MUC6 of the controls and the HNSCC patients and the overall or disease‐free survival of the HNSCC patients. The gene discussed is MUC6; the disease is head and neck squamous cell carcinoma.